| Schedule of Warrants Outstanding |
As of September 30, 2021 and December 31, 2020, the Company had warrants to purchase the underlying common stock outstanding as shown in the table below.
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| 2020 Warrants |
|
|
8,819,904 |
|
|
|
8,842,464 |
|
| 2017 Warrants |
|
|
1,599,645 |
|
|
|
1,599,645 |
|
| 2016 Warrants |
|
|
— |
|
|
|
1,400,000 |
|
| Pfizer Warrant |
|
|
505,617 |
|
|
|
505,617 |
|
| Other warrants (1) |
|
|
1,567 |
|
|
|
2,567 |
|
| |
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
10,926,733 |
|
|
|
12,350,293 |
|
| |
|
|
|
|
|
|
|
|
| Weighted-average exercise price per share |
|
$ |
6.47 |
|
|
$ |
9.14 |
|
| |
|
|
|
|
|
|
|
|
| (1) |
Other warrants are comprised of warrants issued prior to the Company’s initial public offering (“IPO”), generally in exchange for services rendered to the Company. | The following table summarizes information regarding the Company’s warrants outstanding at September 30, 2021:
| |
|
|
|
|
|
|
|
|
| |
|
Shares
Underlying
Outstanding
Warrants |
|
|
|
|
| |
|
|
9,325,521 |
|
|
|
May 27, 2023 |
|
| |
|
|
1,599,645 |
|
|
|
July 25, 2022 |
|
| > $20.00 |
|
|
1,567 |
|
|
|
October 17, 2021 – January 5, 2022 |
|
| |
|
|
|
|
|
|
|
|
| |
|
|
10,926,733 |
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|